miR-1-3p, miR-23b-3p, miR-34a-5p and miR-130a-3p all have conserved binding sites to MET and can influence the progression of pancreatic ductal adenocarcinoma (PDAC) by targeting MET through the PI3K/AKT signaling pathway [16]. The gene discussed is MET; the disease is pancreatic ductal adenocarcinoma.